As a member of cysteine acid proteases family, high expression of CASP1 has been demonstrated to be positively associated with poor prognosis in AML patients and CASP1 inhibition could obviously inhibit the proliferation of AML cells, implying that CASP1 might serve as a potential biomarker to predict the prognosis and therapeutic target for AML patients (60). This evidence concerns the gene CASP1 and acute myeloid leukemia.